Log In
Print
BCIQ
Print
Print this Print this
 

FG-2216, YM311

  Manage Alerts
Collapse Summary General Information
Company FibroGen Inc.
DescriptionSmall molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH)
Molecular Target Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN)
Mechanism of ActionHypoxia-inducible factor prolyl hydroxylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAnemia
Indication DetailsTreat anemia; Treat anemia in chronic kidney disease (CKD) patients who are recombinant erythropoietin (EPO) naïve; Treat renal anemia
Regulatory Designation

Partner

Astellas Pharma Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today